je.st
news
Tag: journal
The Wall Street Journal: Western firms caught off guard as Chinese shoppers flock to Web
2015-06-14 21:52:42| Food - Topix.net
After enjoying nearly three decades of steady growth in its China business, Unilever PLC last year watched sales fall off a cliff. The maker of Dove soap, Lux shampoo and Comfort fabric softener warned in October of a 20% drop in its third-quarter China sales.
Results from Investigational IMPROVE-IT Study of VYTORIN (ezetimibe and simvastatin) Published in the New England Journal of Medicine
2015-06-03 23:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Tracy Ogden, (267) 305-2301orInvestor:Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
results
study
journal
The Wall Street Journal: Safeway to pay hedge funds $44.50 a share to settle buyout suits
2015-06-02 20:13:20| Grocery - Topix.net
Safeway Inc. will pay a group of investment funds about 27% more than other shareholders received when the grocery chain was sold to private-equity-backed Albertsons earlier this year for $7.6 billion, a big win for hedge funds that challenge deals in court. Albertsons will pay three funds, which owned about 6% of Safeway stock, $44.50 a share in cash, or about $134 million more, as part of a court settlement in a buyout-related lawsuit, according to people familiar with the matter.
Tags: share
street
pay
journal
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
2015-05-29 20:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, a well-established form of genetic instability in many cancers characterized by the loss of function of the MMR pathway. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
NFPA Journal Addresses Power Reliability in Hospitals
2015-05-29 18:02:00| Electrical Construction & Maintenance
NFPA Journal recently talked to Eric Cote, a communications and policy consultancy based in Rhode Island, about Powered for Patients read more
Tags: power
journal
addresses
reliability
Sites : [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] next »